www.fdanews.com/articles/177713-aegerion-withdraws-juxtapid-from-eu
Aegerion Withdraws Juxtapid From EU
July 28, 2016
Aegerion Pharmaceuticals has decided to pull its cholesterol-lowering drug Juxtapid from the market and slash 13 percent of its global workforce, the company announced Wednesday.
The company says it plans on entertaining the idea of handing over rights to the drug to an unspecified partner.
The action stems from a wide cost reduction plan brought on by the “impact of competitive therapies on Juxtapid sales,” the company said.